Page 186 - Read Online

Page 14 of 16 Borzio et al. Hepatoma Res 2019;5:15 I http://dx.doi.org/10.20517/2394-5079.2019.11

techniquesin the diagnosis of small hepatocellular carcinoma in cirrhosis. Gut 2010;59:638-44.
10. ICGHN. Pathologic diagnosis of early hepatocellular carcinoma: a report of the International Consensus Group for Hepatocellular
Neoplasia. Hepatology 2008;49:658-64.
11. Roncalli M, Park YN, Borzio M, Sangiovanni A, Sciarra A, et al. Premalignant and early malignant hepatocellular lesions in chronic
hepatitis/cirrhosis. In: Saxena R, editor. Practical Hepatic pathology. A diagnostic approach. 2nd ed. 2018; doi: 10.1016/B978-0-323-
42873-6.00031-7.
12. Tateishi R, Yoshida H, Matsuyama Y, Mine N, Kondo Y, et al. Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a
systematic review. Hepatol Int 2008;2:17-30.
13. Di Tommaso L, Destro A, Seok JY, Balladore E, Terracciano L, et al. The application of markers (HSP70 GPC3 and GS) in liver
biopsies is useful for detection of hepatocellular carcinoma. J Hepatol 2009;50:746-54.
14. Tremosini S, Forner A, Boix L, Vilana R, Bianchi L, et al. Prospective validation of an immunohistochemical panel (glypican 3, heat
shock protein 70 and glutamine synthetase) in liver biopsies for diagnosis of very early hepatocellular carcinoma. Gut 2012;61:1481-7.
15. Di Tommaso L, Destro A, Fabbris V, Spagnolo G, Fracanzani AL, et al. Diagnostic accuracy of clathryn heavy chain staining in a
marker panel for the diagnosis of small hepatocellular carcinoma. Hepatology 2011;53:1549-57.
16. European Association For The Study Of The Of The Liver, European Organisation For Research And Treatment Of Cancer. EASL-
EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 2012;56:908-43.
17. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update.
Hepatology 2011;53:1020-2.
18. Kudo M, Matsui O, Izumi N, Iijima H, Kadoya M, et al. JSH Consensus-based clinical practice guidelines for the management of
hepatocellular carcinoma: 2014 update by the liver cancer study group of Japan. Liver Cancer 2014;3:458-68.
19. Omata M, Lii Cheng AL, Kokudo N, Kudo M, Lee JM, et al. Asia-Pacific clinical practice guidelines on the management of
hepatocellular carcinoma: a 2017 update Hepatol Int 2017;11:317-70.
20. Korean Liver Cancer Study Group (KLCSG), National Cancer Center, Korea (NCC). 2014 Korean liver cancer study group-national
cancer center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol 2015;16:465-522
21. Cartier V, Crouan B, Esvan M, Oberti F, Michalak S, et al. Suspicious liver nodule in chronic liver disease: Usefulness of a second
biopsy. Diagn Interv Imaging 2018;99:493-9.
22. Leoni S, Piscaglia F, Golfieri R, Camaggi V, Vidili G, et al. The impact of vascular and nonvascular findings onthe noninvasive
diagnosis of small hepatocellular carcinoma based on the EASL and AASLD criteria. Am J Gastroenterol 2010;105:599-609.
23. Khalili K, Kim TK, Jang HJ, Yazdi LK, Guindi M, et al. Indeterminate 1-2 cm nodules found on hepatocellular carcinoma
surveillance: biopsy for all, some or none? Hepatology 2011;54:2048-54.
24. Durand F, Regimbeau JM, Belghiti J, Sauvanet A, Vilgrain V, et al. Assessment of the benefits and risks of percutaneousbiopsy before
surgical resection of hepatocellular carcinoma. J Hepatol 2001;35:254-8.
25. Huang GT, Sheu JC, Yang PM, Lee HS, Wang TH, et al. Ultrasound-guided cutting biopsy for the diagnosis of hepato-cellular
carcinoma: a study based on 420 patients. J Hepatol 1996;25:334-8.
26. Silva MA, Hegab B, Hyde C, Guo B, Buckels JA, et al. Needletrack seeding following biopsy of liver lesions in the diagnosis of
hepatocellular cancer: a systematic review and meta-analysis. Gut 2008;57:1592-6.
27. Lee YJ, Lee JM, Lee JS, Lee HY, Park BH, et al. Hepatocellular carcinoma: diagnostic performance of multidetector CT and MR
imaging: a systematic review and meta-analysis. Radiology 2015;275:97-109.
28. Hanna RF, Miloushev VZ, Tang A, Finklestone LA, Brejt SZ, et al. Comparative 13-year meta-analysis of the sensitivity and positive
predictive value of ultrasound, CT, and MRI for detecting hepatocellular carcinoma. Abdom Radiol (NY) 2016;41:71-90.
29. Heimbach J, Kulik LM, Finn R, Sirlin CB, Abecassis MM, et al. AASLD guidelines for the treatment of hepatocellular carcinoma.
Hepatology 2018;67:358-80.
30. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet 2012;379:1245-55.
31. Sersté T, Barrau V, Ozenne V, Vullierme MP, Bedossa P, et al. Accuracy and disagreement of computed tomography and magnetic
resonance imaging for the diagnosis of small hepatocellular carcinoma and dysplastic nodules: role of biopsy. Hepatology
2012;55:800-6.
32. Golfieri R, Renzulli M, Lucidi V, Corcioni B, Trevisani F, et al. Contribution of the hepatobiliary phase of Gd-EOB-DTPA-enhanced
MRI to dynamic MRI in the detection of hypovascular small (≤ 2 cm) HCC in cirrhosis. Eur Radiol 2011;21:1233-42.
33. Ye F, Liu J, Ouyang H. Gadolinium ethoxybenzyl diethylenetriamine pentaacetic acid (Gd-EOB-DTPA)-enhanced magnetic resonance
imaging and multidetector-row computed tomography for the diagnosis of hepatocellular carcinoma: a systematic review and meta-
analysis. Medicine (Baltimore) 2015;94:e1157.
34. Guo J, Seo Y, Ren S, Hong S, Lee D, et al. Diagnostic performance of contrast-enhanced multidetector computed tomography and
gadoxetic acid disodium-enhanced magnetic resonance imaging in detecting hepatocellular carcinoma: direct comparison and a
metaanalysis. Abdom Radiol 2016;41:1960-72.
35. Kitao A, Matsui O, Yoneda N, Kozaka K, Shinmura R, et al. The uptake transporter OATP8 expression decreases during multistep
hepatocarcinogenesis: correlation with gadoxetic acid enhanced MR imaging. Eur Radiol 2011;21:2056-66.
36. Kim HD, Lim YS, Han S, An J, Kim GA, et al. Evaluation of early-stage hepatocellular carcinoma by magnetic resonance imaging
with gadoxetic acid detects additional lesions and increases overall survival. Gastroenterology 2015;148:1371-82.
37. Choi SH, Byun JH, Lim YS, Yu E, Lee SJ, et al. Diagnostic criteria for hepatocellular carcinoma ≤ 3 cm with hepatocyte-specific
contrast-enhanced magnetic resonance imaging. J Hepatol 2016;64:1099-107.
38. Golfieri R, Grazioli L, Orlando E, Dormi A, Lucidi V, et al. Which is the best MRI marker of malignancy for atypical cirrhotic nodules:
hypointensity in hepatobiliary phase alone or combined with other features? Classification after Gd-EOB-DTPA administration. J
Magn Reson Imaging 2012;36:648-57.